Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer.
Patient Education and Counseling.
Times cited: 15
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial.
American Journal of Sports Medicine.
Times cited: 986